OncologyTube.com is the first and only free video sharing website dedicated to helping oncology professionals spread knowledge about cancer research through video, audio and other multimedia.
    • OncologyTube Cancer Articles, News and Videos

      Site: OncologyTube Cancer Articles, News and Videos

    • Products & Pricing
      • Banner Advertising Plans
      • eNewsletter Packages
      • Pre-Roll Advertising
      • Create A Deep Dive Conversation
      • Create a Video Release (VR)
      • Boost Earned Media Only $60
    • 0
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Hungarian (Hungary)
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • How To Self Record An Interview and Presentations
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Buy Advertising Banners
  • Buy Pre-Roll Advertisements
  • Boost Your Earned Media starting at Just $60
  • Create A Deep Dive Conversation
  • Advertising Specifications
  • Our Editorial Process
  • Publisher Calendar

  • Mobile
  • Connect Mobile App

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5595
  • Acute Myelogenous Leukemia 226
  • Bladder 96
  • Bone Metastases 5
  • Brain 79
  • Breast 548
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 209
  • Chronic Myelogenous Leukemia 54
  • Colorectal 172
  • Conference Coverage 1
  • COVID-19 43
  • Gastrointestinal 177
  • General 341
  • Genitourinary 3
  • Head and Neck 110
  • Help 3
  • Hematologic Malignancies 206
  • Hodgkin Lymphoma 34
  • Imaging 2
  • Immunotherapy 179
  • Kidney 392
  • Liver 40
  • Lung 95
  • Lymphoma 235
  • Melanoma and Skin 107
  • Multiple Myeloma 535
  • Myeloproliferative Disease 37
  • News 149
  • Non-Hodgkin Lymphoma 81
  • Non-Small Cell Lung Cancer 554
  • Other 517
  • Ovarian 65
  • Pancreatic 102
  • Patient Resources 51
  • Pediatric 7
  • Prostate 300
  • Sarcoma 13
  • Sickle Cell 22
  • Small Cell Lung Cancer 81
  • Supportive Care 51
  • Testicular 3
  • Urology 16
  • Uterine 9

  • Install
  • Play a Link
  • About
  • Contact
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
  • Bladder
  • Bone Metastases
  • Brain
  • Breast
  • Business Management
  • Cervical
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia
  • Colorectal
  • Conference Coverage
  • COVID-19
  • Gastrointestinal
  • General
  • Genitourinary
  • Head and Neck
  • Help
  • Hematologic Malignancies
  • Hodgkin Lymphoma
  • Imaging
  • Immunotherapy
  • Kidney
  • Liver
  • Lung
  • Lymphoma
  • Melanoma and Skin
  • Multiple Myeloma
  • Myeloproliferative Disease
  • News
  • Non-Hodgkin Lymphoma
  • Non-Small Cell Lung Cancer
  • Other
  • Ovarian
  • Pancreatic
  • Patient Resources
  • Pediatric
  • Prostate
  • Sarcoma
  • Sickle Cell
  • Small Cell Lung Cancer
  • Supportive Care
  • Testicular
  • Urology
  • Uterine
Yelena Y. Janjigian, MD @YJanjigianMD @sloan_kettering @MSKCC @merck #GastricCancer #GastroesophagealCancer #Cancer #Research FDA Approves Pembrolizumab With Trastuzumab And Chemotherapy ...
0:14:31

Yelena Y. Janjigian, MD @YJanjigianMD @sloan_kettering @M...

Yelena Y. Janjigian, MD from Memorial Sloan Kettering Cancer Center speaks about ASCO 2021 Abstract FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.

Link to Article:
https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-combined-with-trastuzumab-and-chemotherapy-as-first-line-treatment-in-locally-advanced-unresectable-or-metastatic-her2-positive-gastric-or-g/

Merck's anti-PD-1 therapy, KEYTRUDA, has been approved by the United States Food and Drug Administration (FDA) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer. This indication received accelerated approval based on tumor response rate and response durability; continued approval for this indication could be dependent on clarification and explanation of clinical advantage in confirmatory trials. This approval is based on findings from the ongoing Phase 3 KEYNOTE-811 trial, which found that KEYTRUDA in combination with trastuzumab and either 5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin resulted in a statistically significant objective response rate (ORR) of 74 percent (95 percent CI, 66-82) for patients who received the KEYTRUDA-containing regimen versus 52 percent The full response rate was 11% and the partial response rate was 63 percent in patients who administered the KEYTRUDA regimen. The full response rate was 3.1 percent and the partial response rate was 49 percent in patients who received trastuzumab and chemotherapy alone.

Immune-mediated adverse reactions, which can be serious or lethal, can affect any organ system or tissue, and they can affect several body systems at the same time. Pneumonitis, colitis, leukemia, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and risks with allogeneic hematopoietic stem cell transplantation are all immune-mediated adverse reactions that may arise before or after treatment with KEYTRUDA. The list of important immune-mediated adverse reactions does not contain both serious and fatal immune-mediated adverse reactions. To ensure that KEYTRUDA is used safely, it is important to identify and control immune-mediated adverse reactions as soon as possible. KEYTRUDA should be delayed or permanently discontinued, and corticosteroids should be prescribed if appropriate, depending on the nature of the adverse reaction. Infusion-related responses to KEYTRUDA may be serious or life-threatening. When given to a pregnant woman, KEYTRUDA has the potential to damage the fetus due to its mechanism of action. See "Selected Important Safety Facts" below for more information.

The FDA's Real-Time Oncology Evaluation (RTOR) pilot software was used to review this request.

Information in Support of the Approval

KEYNOTE-811 (ClinicalTrials.gov, NCT03615326) was a multicenter, randomized, double-blind, placebo-controlled study that included 692 patients with HER2-positive advanced gastric or GEJ adenocarcinoma who had not previously undergone systemic treatment for metastatic disease. The chemotherapy protocol (5-fluorouracil [5-FU] plus cisplatin [FP regimen] or capecitabine plus oxaliplatin [CAPOX regimen]) and regional area (Europe/Israel/North America/Australia, Asia, or Rest of the World) were used to stratify the randomization. Patients were randomly assigned to one of the following treatment arms (1:1):


KEYTRUDA 200 mg, trastuzumab 8 mg/kg on first infusion and 6 mg/kg in subsequent cycles, followed by investigator's options of cisplatin 80 mg/m2 for up to six cycles and 5-FU 800 mg/m2/day for five days (FP) or oxaliplatin 130 mg/m2 for up to six cycles and capecitabine 1,000 mg/m2 bid for 14 days (CAPOX). On Day 1 of each series, KEYTRUDA was given before trastuzumab and chemotherapy; or

Placebo, trastuzumab, and the investigator's option of chemotherapy regimen: FP or CAPOX, dosed as before.

Except for oral capecitabine, all research drugs were given as an intravenous infusion every three weeks. Treatment with KEYTRUDA was extended for a period of 24 months or before RECIST v1.1 identified worsening of disease as assessed by blinded independent central examination (BICR) or intolerable toxicity. ORR and length of reaction (DOR) by BICR using RECIST v1.1, updated to adopt a maximum of 10 target lesions and a maximum of five target lesions per organ, were major outcome measures measured in an interim efficacy study.


ORR and DOR were tested among the first 264 patients randomized at the time of the interim study. The 264 patients had a median age of 62 years (range, 19 to 84), with 41% being 65 or older; 82 percent were male; 63 percent were white, 31 percent Asian, and 0.8 percent were black; 47 percent had an Eastern Cooperative Oncology Group (ECOG) PS of 0, and 53 percent had an ECOG PS of 1. Ninety-seven percent of patients had stage IV metastatic illness, and three percent had locally progressed unresectable disease. Eighty-seven percent of tumors had PDL1 with a CPS 1 expression. Ninety-one percent (n=240) of the tumors were not microsatellite instability-high (MSIH), two percent (n=2) were MSIH, and eight percent (n=22) had no identified status. CAPOX was given to 87 percent of the patients.


Patients who received KEYTRUDA in combination with trastuzumab and chemotherapy had a statistically important better ORR than those who received placebo in combination with trastuzumab and chemotherapy.

102 Views
1 year Ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Gastrointestinal

ASCO 2022 Esophageal Cancer Question & Answer
0:07:23
ASCO 2022 Esophageal Cancer Question & Answer
7 Views
6 months Ago
MOASC
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
ASCO 2022 Esophageal In-Depth Slides: MOASC Spotlight
0:29:20
ASCO 2022 Esophageal In-Depth Slides: MOASC Spotlight
230 Views
6 months Ago
MOASC
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Article: Transcript: What Is ECOG-ACRIN EA2142? And Why Should You Care? - Jennifer R. Eads, MD @PennMedicine #ASCO22 #OncoTwitter
Article: Transcript: What Is ECOG-ACRIN EA2142? And Why S...
16 Views
8 months Ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Transcript Anal Cancer in HIV patients, ANCHOR Study Results
Transcript Anal Cancer in HIV patients, ANCHOR Study Results
13 Views
8 months Ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Article: Transcript: How Immune Checkpoint Inhibitors Get Scored With 27-gene IO - Matthew Varga, PhD @OncocyteCorp #ASCO22 #OncoTwitter
Article: Transcript: How Immune Checkpoint Inhibitors Get...
10 Views
8 months Ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Audio: What Is ECOG-ACRIN EA2142? And Why Should You Care? - Jennifer R. Eads, MD @PennMedicine #ASCO22 #OncoTwitter
0:07:33
Audio: What Is ECOG-ACRIN EA2142? And Why Should You Care...
5 Views
8 months Ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Video: What Is ECOG-ACRIN EA2142? And Why Should You Care? - Jennifer R. Eads, MD @PennMedicine #ASCO22 #OncoTwitter
0:07:33
Video: What Is ECOG-ACRIN EA2142? And Why Should You Care...
298 Views
8 months Ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast Anal Cancer in HIV patients, ANCHOR Study Results
0:21:27
Podcast Anal Cancer in HIV patients, ANCHOR Study Results
29 Views
8 months Ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Anal Cancer in HIV patients, ANCHOR Study Results
0:21:27
Anal Cancer in HIV patients, ANCHOR Study Results
110 Views
8 months Ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Audio: How Immune Checkpoint Inhibitors Get Scored With 27-gene IO - Matthew Varga, PhD @OncocyteCorp #ASCO22 #OncoTwitter
0:09:45
Audio: How Immune Checkpoint Inhibitors Get Scored With 2...
2 Views
8 months Ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
DetermaIO algorithm and qPCR assay
0:09:45
DetermaIO algorithm and qPCR assay
117 Views
8 months Ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast Karyn Goodman, MD @KarynAGoodman @IcahnMountSinai # ASCOGI22 #SKYSCRAPER07 #ESCC Phase III SKYSCRAPER-07 Study
0:08:20
Podcast Karyn Goodman, MD @KarynAGoodman @IcahnMountSinai...
20 Views
1 year Ago
Gastrointestinal GI Cancer Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

comments@oncologytube.com Copyright 2023 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592